Regulatory News ODAC gives thumbs-up to GSK plan to build on MSK rectal cancer study of dostarlimab that produced 100% response February 10, 2023Vol.49 No.06By Jacquelyn Cobb and Paul Goldberg
Guest Editorial ODAC clears a path for dostarlimab, a drug that may “beat the reaper” in locally advanced rectal cancer February 10, 2023Vol.49 No.06By Richard M. Goldberg
NCI Bertagnolli raises paylines, creates Clinical Trials Innovation Unit, and announces National Cancer Plan February 10, 2023Vol.49 No.06By Matthew Bin Han Ong
White House Biden places cancer in top spot on Unity Agenda; announces new Moonshot programs February 10, 2023Vol.49 No.06By Matthew Bin Han Ong
Drugs & Targets FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer February 10, 2023Vol.49 No.06
In Brief Laleh Amiri-Kordestani named acting associate director for cardio-oncology at FDA OCE February 03, 2023Vol.49 No.05
Drugs & Targets Jaypirca receives FDA accelerated approval for R/R mantle cell lymphoma February 03, 2023Vol.49 No.05
Drugs & Targets Orserdu & companion diagnostic for ER+, HER2-, ESR1-mutated advanced breast cancer receive FDA approval February 03, 2023Vol.49 No.05
Drugs & Targets RefleXion receives FDA clearance for SCINTIX biology-guided radiotherapy February 03, 2023Vol.49 No.05
Drugs & Targets FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma February 03, 2023Vol.49 No.05
